Glioblastoma (GBM) is the most common and invasive adult brain cancer. The rapid invasion of cancer cells into the normal brain is a major cause of treatment failure, yet the mechanisms that regulate this process are poorly understood. We have identified a novel mechanism of brain cancer invasion. We show that downregulated in renal cell carcinoma (DRR), which is newly expressed in invasive gliomas, recruits AKT to focal adhesions. This DRR-induced pathological relocalization of AKT bypasses commonly altered upstream signaling events and leads to AKT activation and invasion. We also developed an oligonucleotide therapeutic that reduces DRR expression and prevents glioma invasion in an in vivo preclinical model of the disease. Our findings identify DRR as a novel GBM target and show that oligonucleotides targeting DRR is a novel therapeutic approach for the treatment of DRR-positive GBMs.
INTRODUCTION
Glioblastoma (GBM) is the most common adult brain cancer. The median survival with current therapy is 14.6 months. 1, 2 Cancer cell invasion into the normal brain is a major contributor to this rapid treatment failure, yet the mechanisms governing this phenomenon remain poorly understood.
The epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway is a major driver of GBM invasion. 3 EGFR activates the lipid kinase PI3K, which then phosphorylates PI(4,5)P 2 converting it to PI(3,4,5)P 3 . PIP 3 (phosphatidylinositol (3, 4, 5) -triphosphate) in turn binds the pleckstrin homology domain of AKT thereby recruiting it to the cell membrane. Once there, AKT is activated by phosphorylation at Thr308 and Ser473 by 3-Phosphoinositide-dependent protein kinase 1 and mammalian target of rapamycin complex 2, respectively. [4] [5] [6] [7] [8] Activated AKT translocates from the membrane to the cytosol and the nucleus, where it drives downstream pathways affecting cell proliferation, survival, metabolism and invasion. [9] [10] [11] This cascade can be terminated by phosphatase and tensin homolog (PTEN), which interrupts PIP 3 signaling by dephosphorylating PIP 3 to PIP 2 . 3, 8, 10 Oncogenic alterations of EGFR, PIK3CA and PTEN have been identified in GBM. 12 Combined, this pathway is deregulated in over 80% of these tumors, and elevated phosphorylated AKT (pAKT) levels are found in 85% of GBMs. [12] [13] [14] EGFR is thus an attractive therapeutic target, yet clinical trials testing EGFR inhibitors in GBM have yielded disappointing results. [15] [16] [17] Importantly, AKT can also be activated independently of receptor tyrosine kinase (RTK) or PI3K activity. The viral oncogene v-akt is created by the addition of a myristoylation signal to the amino terminus of AKT; this confers constitutive activation to AKT, allowing it to associate with the cell membrane without the need for upstream RTK or PI3K involvement. 18, 19 Similarly, a mutation in the pleckstrin homology domain of AKT leads to the association of AKT with the cell membrane and constitutive activation in breast, colorectal and ovarian cancers. 20 Thus, events promoting AKT localization to the cell membrane can be sufficient for its activation. Downregulated in renal cell carcinoma (DRR) is a recently identified driver of glioma invasion. 21 It has been reported to function as a putative tumor suppressor protein. [22] [23] [24] Normally expressed in the neurons, DRR has been shown to bundle actin and regulate neurite outgrowth. 25 In the context of gliomas, it is expressed in both low-and high-grade gliomas but not in normal glia. 21 DRR localizes along stress fibers, at focal adhesions (FAs) and within the nucleus, and its expression promotes FA turnover. 21 Despite the evidence that DRR participates in glioma invasion, the underlying mechanism is unknown.
As the EFGR/PI3K-PTEN/AKT pathway is a driver of GBM invasion that is altered in the large majority of GBMs, and DRR is overexpressed in invasive gliomas, we tested whether DRR is involved in this pathway. We found that DRR expression leads to elevated AKT activation by recruiting AKT to FAs in a manner dependent on SRC-family kinases (SFKs) and cell adhesion. We also found that reduction of DRR expression using antisense oligonucleotides (AOs) prevents glioma invasion in an in vivo xenograft mouse model. Therefore, our study reveals that DRR is a novel GBM target and that AOs targeting DRR is a promising new therapeutic approach to prevent brain cancer invasion.
RESULTS

DRR induces AKT phosphorylation and this event is independent of EGFR signaling
The EGFR/PI3K-PTEN/AKT signaling pathway is altered in over 80% of GBMs, and pAKT is elevated in over 85% of GBMs. [12] [13] [14] In this study, we used the prototypical human GBM-derived U251 cells (CTL) as a model to create a stable DRR-overexpressing (DRRov) cell line. We previously characterized these cell lines and found that upon DRR overexpression cells become more invasive and the rate of FA turnover is increased. 21 To determine whether DRR affects AKT activation, we assessed pAKT levels in both CTL and DRRov cells. Gain of DRR expression was associated with significantly elevated AKT phosphorylation at both the Thr308 and Ser473 sites compared with CTL cells, whereas total AKT expression was similar in both cell lines (Figure 1a ). pAKT immunolabeling also revealed significantly elevated pAKT expression in DRRov cells compared with CTL cells (Figure 1b) . As EGFR signaling is altered in 45-55% of GBMs and is a well-characterized activator of the PI3K/AKT pathway under normal and pathophysiological conditions, [12] [13] [14] we investigated EGFR protein expression and phosphorylated EGFR levels in the context of DRR expression. We found that DRRov cells express significantly higher levels of EGFR and activated EGFR, as indicated by phosphotyrosine ( Figure 1c ) and phosphorylated EGFR (Tyr 845) (Supplementary Figure 1a) , as well as cell surface EGFR compared with CTL cells (Figure 1d ). We analyzed EGFR mRNA levels by quantitative real-time PCR in DRRov and CTL cells and did not observe a significant difference between cell lines, suggesting post-transcriptional regulation (Supplementary Figure 1b) .
We used the EGFR kinase inhibitors AG1478 26 and gefitinib 27 to determine whether this increased EGFR/phosphorylated EGFR expression was responsible for the DRR-induced AKT phosphorylation. We treated CTL cells with EGF and observed an increase in phosphotyrosine and pAKT levels, which were inhibited after treatment with EGF in the presence of AG1478. We also observed a decrease in phosphotyrosine levels in DRRov cells after AG1478 treatment, whereas the levels of pAKT did not change (Figure 1e ). Gefitinib, while effectively blocking EGFinduced EGFR phosphorylation in both cell lines, also did not decrease pAKT levels in DRRov cells (Supplementary Figure 1c) . Consistent with this observation, we found that EGFR inhibition did not significantly reduce DRRov cell invasion in a threedimensional invasion assay (Figures 1f, g ). Thus, although EGFR/phosphorylated EGFR expression is elevated in DRRov cells, it is not involved in DRR-induced AKT phosphorylation or cell invasion.
DRR-induced AKT phosphorylation is SFK-and integrin-dependent Activating inputs that can lead to AKT phosphorylation include RAS/RAF/MEK/ERK kinases, Rho-GTPases, integrin-linked kinase (ILK), SFKs, FA kinase (FAK) and PI3K. 14, [28] [29] [30] [31] [32] We tested each of these inputs in order to determine how DRR regulates AKT activation.
The MEK inhibitor U0126 is a non-ATP competitive inhibitor that targets MEK1 and MEK2 and effectively inhibits downstream ERK phosphorylation 33 (see Supplementary Figure 2a ). We found that MEK inhibition did not reduce pAKT levels in DRRov cells (Figure 2a ). Rho-family GTPases are involved in AKT regulation and also act downstream of AKT to regulate cytoskeletal dynamics and cell movement. 29, [34] [35] [36] Application of the Rho A, B and C inhibitor, exoenzyme C3 transferase, to DRRov cells predictably altered cytoskeletal architecture and cell morphology by reducing stress fiber levels and collapsing cell structure (see Supplementary  Figure 2b ). However, this treatment did not affect pAKT levels ( Figure 2b ).
ILK operates between integrins and RTKs and is an important activator of AKT. 31, 37 ILK expression was abolished in DRRov cells using an ILK-targeted small interfering RNA oligonucleotide and was unaltered after transfection with a scrambled sequence ( Figure 2c ). However, silencing ILK expression did not decrease pAKT levels (Figure 2c ).
SFKs are well-characterized effectors of integrin signaling and are key regulators of FA dynamics. 38 Application of the SFK inhibitor PP2 (5 mM) to DRRov cells reduced pAKT levels, whereas the inactive analog PP3 had no significant effect on pAKT levels Figure 3a) and observed reduced pAKT levels; suggesting that SFKs are regulating DRR-induced AKT activation in a cell-matrix adhesion-dependent manner.
Activation of FAK is an early event following adhesion, is dependent upon SFK activity and leads to AKT phosphorylation. 38, 39 To test FAK involvement in AKT phosphorylation, we blocked FAK activity by treating DRRov cells with the FAK inhibitor PF-228 for 1 h before seeding cells on fibronectin. This treatment effectively prevented the phosphorylation of FAK at Y397, yet pAKT levels were not reduced (Figure 2f ), suggesting that DRRinduced AKT phosphorylation occurs independently of FAK activity.
To determine whether PI3K is involved, we treated DRRov cells with the PI3K inhibitors LY294002 (5, 10 and 20 mM) and wortmannin (100 nM). Although AKT phosphorylation was effectively inhibited in CTL cells after treatment with both inhibitors, neither LY294002 nor wortmannin prevented AKT phosphorylation in DRRov cells (Figure 2g, Supplementary Figure 3b) . Following our observation that SFK inhibition of AKT phosphorylation was adhesion-dependent, we examined whether PI3K inhibition would be effective in reducing pAKT levels in an adhesion-dependent context. By repeating the experiments on fibronectin, we found that even low concentrations (5 mM) of LY294002 could decrease AKT phosphorylation (Figure 2h ). These findings reveal the importance of integrin-mediated adhesion in DRR-induced AKT phosphorylation.
Integrins interact with the extracellular-matrix through the RGD (arginine-glycine-aspartic acid) amino-acid sequence. 40 We used a modified RGD peptide that competes with the RGD domain of the extracellular-matrix for integrin binding to directly test the adhesion dependence we have observed. We treated cells in suspension with the modified RGD peptide for 30 min before seeding cells on fibronectin. This treatment gave rise to a nonadherent population of cells. In this non-integrin binding cell population there was a loss of AKT phosphorylation (Figures 3a, b) . Similarly, AKT was not phosphorylated in DRRov cells that were maintained in suspension without RGD treatment (Figures 3a, b) .
DRR recruits AKT to FAs
We have previously showed that within the cytoplasm, DRR is localized at FAs and along stress fibers. 21 Our results showing that DRR regulates AKT phosphorylation in an adhesion-and SFKdependent manner suggest that DRR may be recruiting AKT to FAs. We tested this by immunolabeling AKT and pAKT in DRRov and CTL cells seeded on fibronectin. For each time point studied (30 m to 6 h), both AKT and pAKT shared an overlapping expression pattern with vinculin in DRRov cells (Figure 3c ). In contrast, AKT and pAKT were expressed diffusely in the cytoplasm of CTL cells (Figure 3c ).
As both DRR and SFKs regulate FA dynamics, we next tested whether SFKs are involved in DRR-induced AKT recruitment to FAs. DRRov cells seeded on fibronectin and treated with 10 mM PP2 developed FAs containing vinculin, yet pAKT was not observed at these FAs (Figure 3d ). To further explore the possibility that DRR recruits AKT to FAs, we utilized a mutant form of DRR, DRR DPEPE , which does not localize to FAs. 21 We found that when this form of DRR is expressed, we did not observe colocalization between pAKT and FAs (Figure 3e) , and pAKT levels were not elevated (Figure 3f ).
SFK and PI3K inhibitors prevent DRR-induced invasion
Having identified a mechanistic link between adhesion, DRR, SFK/ PI3K activity and AKT, we next tested whether this signaling axis directly affected the invasive properties of DRRov cells. To this end, we tested whether SFK or PI3K inhibition could prevent DRRov cells from invading in a three-dimensional invasion assay. We found that treatment of DRRov spheroids with either 10 mM PP2 or LY294002 significantly reduced the invasiveness of these cells at 48 and 96 h (Figures 4a, b) , whereas CTL spheroids showed significant reductions only at 96 h (Figures 4a, c) . We also observed reduced invasion of DRRov spheroids in the presence of LY294002 and 5-Fluorouracil, an inhibitor of cell division 41 ( Supplementary  Figure 4) . This observation suggests that the SFK/PI3K/AKT pathway is implicated in DRR-mediated invasion.
Antisense oligonucleotide-mediated DRR ablation prevents invasion in a GBM mouse model We have shown that DRR regulates AKT phosphorylation to drive invasion, and that treatment with SFK and PI3K inhibitors can significantly reduce this invasion. Our next step was to test whether reduction of DRR expression could prevent brain cancer invasion in vivo. Direct application of AOs to brain cancers could be an effective treatment modality. 42 We designed AOs targeting DRR after having previously shown that malignant glioma cells expressing negligible levels of DRR displayed decreased invasive properties in vivo compared with those overexpressing DRR. 21 GBM stem cell lines cultured in the absence of serum closely reproduce the pathological features of human GBMs in in vivo intracranial models. 43 First, we assessed DRR levels in a human GBM stem cell line (hGSC) and found that it was expressed (Figure 5a ). Upon treatment with DRR-targeted AOs, we were able to efficiently knock down DRR levels and observed a simultaneous decrease in pAKT compared with scramble AOs (Figure 5a ). These findings indicate that DRR regulates AKT signaling in a glioma stem cell model and confirm our data from the DRRov cells.
We extended these findings to an in vivo model. hGSCs treated with Cy5-conjugated control AOs and AOs targeting DRR were implanted in the striatum of immuno-compromised CD1 mice. The stem cell marker Sox-2 was used to identify all implanted cells, whereas Cy5 labeling was used to identify tumor cells that had been treated with AOs. Whereas cancer cells treated with Cy5-conjugated control AOs readily invaded the peritumoral brain well beyond the tumor site (Figure 5b upper panels, c), cancer cells treated with anti-DRR AOs did not, but instead remained within the well circumscribed tumor mass (Figure 5b lower panels, c). These findings show that targeting DRR in vivo is an efficient approach to reduce brain cancer invasion and suggest that AOs are an effective method for reducing DRR levels.
DISCUSSION
Our studies identify a novel mechanism for AKT activation and invasion in brain cancer. We have also developed a promising anti-invasive therapeutic to prevent brain cancer invasion. We show that DRR, which is newly expressed in invasive gliomas, 21 recruits AKT to FAs in a SFK-and adhesion-dependent manner. We also show that the inhibition of SFKs, and to a lesser extent PI3K, prevents AKT phosphorylation. Finally, we show that the reduction of DRR expression using AOs targeting DRR prevents invasion in a xenograft mouse model of the disease.
Mutations in AKT that target it to the cell surface, which bypass upstream signaling events (such as RTK/PI3K activation), can be sufficient for full AKT phosphorylation, 18 and these alterations have been described in cancers. 20 Our findings support a model in which DRR pathologically relocalizes AKT to FAs in a SFKdependent manner. AKT is phosphorylated at FAs and this elevated level of activated AKT remains detectable for at least 6 h, suggesting that under these conditions AKT is hyper-active. Furthermore, we observed that PI3K inhibition only reduces AKT phosphorylation upon integrin activation, suggesting that diffusely localized PI3K does not have a role in AKT phosphorylation in the presence of DRR. These results support a novel mode of AKT activation following its recruitment to integrinbased FAs.
AKT is activated in the large majority of GBMs, and emerging evidence suggests that AKT has a role in GBM invasion. 44 As AKT is not frequently mutated in GBM, its activation is presumed to be under the control of upstream RTKs. Our findings that AKT activation is not under the control of EGFR in DRR-positive glioma cells may provide an explanation for the negative results of EGFR inhibitors in clinical trials. 45, 46 In contrast, our studies point to DRR as an important molecular player in GBM invasion, making DRR a valuable target for therapeutics as well as a potentially useful biomarker for EGFR-independent brain cancer invasion.
Our results highlight the importance of SFKs and integrins as targets to prevent GBM invasion. Dasatinib is a potent SRC and SFK inhibitor that has been shown to inhibit migration and invasion of GBM cells. 47, 48 These data correlate well with our findings and suggest that SFK inhibitors may be useful in preventing DRR-induced brain cancer invasion. A phase I/II trial involving patients with newly diagnosed GBM is currently testing dasatinib combined with radiotherapy and concomitant temozolomide, followed by adjuvant dasatinib plus temozolomide. 49, 50 The integrin inhibitor Cilengitide is also being tested as a first-line therapy in GBM. 51 In these trials progression-free survival and overall survival are primary end points. Given our findings, it would be relevant to assess the extent of tumor invasion on surveillance imaging as another important biomarker of efficacy.
AOs delivered to the resection cavity of GBM patients via implanted catheters, thereby bypassing the need for systemic delivery is currently in Phase II/III clinical trials. Clinical trials testing AOs targeting transforming growth factor b2 have shown encouraging results. 42 We have developed an AO that targets DRR expression and prevents brain cancer invasion in a xenograft model. As GBM invasion into normal brain is a local event in over 85% of patients, 52 delivery of AOs targeting invasion directly into the resection cavity provides treatment to the most relevant area with minimized toxicity. Upon tumor resection, catheters can be placed directly into the resection cavity providing a simple mechanism for routine AO delivery. Given that this therapeutic modality is currently being investigated, our findings suggest that anti-DRR AOs could be a promising and practical therapy to treat DRR-positive GBM patients, with a reduction in invasion as a treatment endpoint. Cell culture DRRov cells: AmphoPack 293 cells were first transfected with the DRR plasmid pLib (Clontech, Mountain View, CA, USA) using Lipofectamine reagent according to the manufacturer's protocol. Forty-eight and seventytwo hours post transfection, retrovirus was collected and added to the human GBM-derived U251 cell line. Stable cell lines were selected with G418 media. U251 brain cancer cells and DRR-overexpressing cells were cultured as previously described. 21 Human GBM stem cells (hGSCs) were kindly provided by Dr Samuel Weiss (University of Calgary). hGSCs were isolated as previously performed 53 and expanded in neurosphere cultures. Spheres were cultured in complete Neurocult-NS-A proliferation medium (Neurocult basal medium containing: Neurocult-NS-A differentiation supplement at a concentration of 1/10 dilution, 20 ng/ml rh EGF, 20 ng/ml rh bFGF and 2 mg/ml Heparin) from Stemcell Technologies (Vancouver, BC, Canada). When spheres appear large enough for passaging (o300 mm in diameter), they were collected in tubes and spun at 1200 r.p.m. for 3 min. To dissociate the spheres, 700 ul of Accumax (Millipore) was added to the cell pellet and incubated for 5 min at 37 1C, they were then washed with phosphate-buffered saline, centrifuged and resuspended in complete Neurocult-NS-A proliferation medium and seeded at a concentration of 200 000 cells/flask.
MATERIALS AND METHODS
Antibodies and reagents
Pharmacological inhibition assays
Cells were treated overnight with 1 mM AG1478 or 5 mM gefitinib before being treated with 50 ng/ml EGF either alone or in the presence of 1 mM AG1478 or 5 mM gefitinib for 10 min at 37 1C; with 5-20 mM U0126 for 2 h at 37 1C, then stimulated with EGF alone or in the presence of U0126 for 10 min at 37 1C before lysis; with 2 mg/ml C3 transferase for 5 h at 37 1C before lysis; with 5 or 10 mM PP2 (or PP3) or 5 mM SU6656 for 5 h at 37 1C before lysis; with 200 nM PF-228 for 1 h at 37 1C before lysis; with 5-20 mM LY294002 or 100 nM wortmannin for 2 h or 1 h, respectively, and then stimulated with EGF alone or in the presence of LY294002 or wortmannin for 10 min at 37 1C before lysis. For the experiments in which fibronectin was used, 24-well plates were coated with 50 mg/ml fibronectin overnight at 4 1C. Fibronectin was then removed and the plate was allowed to air dry at room temperature for B1 h before the addition of cells. All inhibitors were dissolved in dimethyl sulfoxide therefore an equivalent volume of dimethyl sulfoxide was used as a control. 
RGD assay
Plates were coated with fibronectin. Cells were treated with 500 mM RGD in suspension on a rotating platform at room temperature for 30 min. A total of 200 000 cells/well were plated onto fibronectin for 30 min. Cells that did not adhere were removed and lysed.
Immunocytochemistry
Cells were grown to B70% confluency on glass coverslips (with or without fibronectin) in supplemented Dulbecco's Modified Eagle Medium. Cells were fixed with 3% paraformaldehyde, then permeabilized with 0.5% Triton X-100 before being incubated with indicated primary and secondary antibodies. Images were captured with the LSM 700 confocal microscope using a Â 60 oil immersion objective. Where indicated, fluorescence was quantified using ImageJ (http://rsbweb.nih.gov).
Three-dimension invasion assay
Invasion assays were performed as previously described. 21 Briefly, 25 000 cells/drop were plated onto the lid of a 10 cm Petri dish and hung to allow spheroid formation. On the third day, spheroids were transferred to 2% agar. On the sixth day, spheroids were implanted into a collagen type I matrix and appropriate media was added (regular Dulbecco's Modified Eagle Medium ± 1 mM 5-Fluorouracil or supplemented with 10 mM PP2/ LY294002/AG1478 ± 1 mM 5-Fluorouracil). Spheroids were imaged over 24 h intervals with a Zeiss light microscope Â 5 objective. Four spheroids/ condition from three independent experiments were used to quantify invasion. Invading area was measured by calculating the extreme diameter at four different angles and by subtracting the extreme diameter of the spheroids at time zero.
Antisense oligonucleotides
AOs were designed to target DRR mRNA (NM_007177) in the open reading frame at position 576-595. Scrambled AOs are non-targeting negative control sequences. AOs were synthesized on an ABI 3400 DNA synthesizer from Applied Biosystems (Burlington, ON, Canada). AOs were purified by reverse phase HPLC using a Waters 1525 HPLC and a Varian Pursuit 5 semipreparative reverse phase C18 column. AOs were characterized by Liquid chromatography-mass spectrometry.
Animal work
All animal procedures were approved by the Institution's Animal Care Committee and performed according to the guidelines of the Canadian Council of Animal Care. Female CD1 athymic nude mice (Charles River, Canada) were anesthetized at 6 weeks of age using intraperitoneal injection containing Ketamine, Xylazine and Acepromazine. The mice were placed on a stereotaxic apparatus and a midline scalp incision was made. A burr-hole (3-5 mm) was created 2.2 mm lateral to the bregma using a high-powered drill. The injection needle containing 100 000 cells pretreated with the antisense (20 nM; for 72 h) was then lowered into the burr-hole to a depth of 3.0 mm to allow tumor implantation at the center of the caudate nucleus. Animals (n ¼ 18) were euthanized 3 weeks post implantation, and brains were harvested following phosphate-buffered saline/formalin animal perfusion.
Formalin fixation, tissue processing Harvested brain specimens were placed in 10% neutral-buffered formalin for 72 h at room temperature immediately following the killing of the animal. Following formalin fixation, specimens were processed and paraffin embedded, and 5 mm tissue sections were prepared and mounted on a poly-L-lysine-coated glass slides.
Antigen retrieval and immunolabeling
Samples were baked in a standard laboratory oven at 60 1C for 1 h. Antigen retrieval was done using citrate buffer (pH 6.0) and pressure cooking for 10 min. The slides were blocked for 40 min, incubated for 1 h with antihuman Sox-2 primary antibody (R&D) and 20 min with secondary antibody. Imaging was performed with a LSM 700 confocal microscope using a Â 20 objective. Three mice/condition from three independent experiments were used to quantify invasion. The number of cells that invaded beyond 100 mm of the epicenter of the tumor were counted.
Statistical analysis
Each experiment was performed at least three times (n ¼ 3) from independent biological replicates. Data were analyzed with the statistical software GraphPad Prism 5 and has been presented as mean ± standard error of mean (s.e.m). Po0.05 was considered statistically significant.
